COMPOSITIONS OF ENRICHED AND MODIFIED CELLS

Abstract: the invention relates to a cell solution and composition optimized for selective isolation, genetic modification, and therapeutic use of target cells, such as t-cells, nk-cells, or hematopoietic stem cells. the solution comprises at least 90% target cells, with a minimum of 75% genetically modified cells, achieving high purity and viability rates through a functionally closed system. the method incorporates microbubble-based cell selection using lipid-shell microbubbles functionalized with antibodies or aptamers for high-affinity binding. the microbubbles enable buoyant separation under centrifugal force, with reversible binding mechanisms allowing for controlled cell release. the genetically modified cells exhibit functional transgene expression and retain therapeutic efficacy, including cytokine production upon activation. additionally, the composition minimizes contaminants such as non-target cells or microbubble fragments, ensuring suitability for downstream therapeutic applications. this innovation supports high-efficiency, contamination-free cell processing for advanced immunotherapies and regenerative medicine.

Inventor(s): Jonathan Ellis, Philip H. Coelho

CPC Classification: A61K35/17 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250213617